The future implications and indications of anti-vascular endothelial growth factor therapy in ophthalmic practice

The future implications and indications of anti-vascular endothelial growth factor therapy in ophthalmic practice

In the last few years anti-vascular endothelial growth factor (VEGF) therapy has changed the paradigm in the treatment of neovascular age-related macular degeneration (ARMD). Besides, its potential use in the treatment of diabetic retinopathy and other possible proliferative vascular disorders has a...

Full description

Bibliographic Details
Main Authors:	Hussain Nazimul, Ghanekar Yashoda, Kaur Inderjeet
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2007-01-01
Series:	Indian Journal of Ophthalmology
Subjects:	Age-related macular degeneration angiogenesis anti-vascular endothelial growth factor bevacizumab complement pathway pegaptanib pigment epithelium derived factor ranibizumab
Online Access:	http://www.ijo.in/article.asp?issn=0301-4738;year=2007;volume=55;issue=6;spage=445;epage=450;aulast=Hussain

Similar Items

An overview on age related macular degeneration and recent advances in its management
by: SOBIA N., et al.
Published: (2014-03-01)

Anti-VEGF agents in the treatment of diabetic macular edema
by: Vladimir Iosifovich Konenkov, et al.
Published: (2013-12-01)

Pegaptanib sodium for ocular vascular disease
by: Shukla Dhananjay, et al.
Published: (2007-01-01)

Comparison of Ranibizumab and Pegabtanib Sodium Monotherapies in Terms of Rates of Stabilization After the First Three Doses
by: Nilüfer Koçak, et al.
Published: (2012-05-01)

ANGIOGENESIS IN PROLIFERATIVE DIABETIC RETINOPATHY: RERSPECTIVES OF ANTI-VEGF THERAPY (REVIEW OF LITERATURE)
by: V. I. Konenkov, et al.
Published: (2015-12-01)

Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Oedema: Is It Safe?
by: Kuan Hao Yee, et al.
Published: (2017-10-01)

Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Oedema: Is It Effective?
by: Kuan Hao Yee, et al.
Published: (2017-10-01)

Comparison of subconjunctivally injected bevacizumab, ranibizumab, and pegaptanib for inhibition of corneal neovascularization in a rat model
by: Cem Küçükerdönmez, et al.
Published: (2013-04-01)

The effects of anti-VEGF drugs on the retinal pigment epithelium and inner segment after intravitreal injection in the monkeys
by: Nan Su, et al.
Published: (2016-06-01)

Effects of ranibizumab (Lucentis®) and bevacizumab (Avastin®) on human corneal endothelial cells
by: Patrick R. Merz, et al.
Published: (2018-12-01)

Effects of FTMT Expression by Retinal Pigment Epithelial Cells on Features of Angiogenesis
by: Undral Buyandelger, et al.
Published: (2020-05-01)

Comparison of bevacizumab and ranibizumab in age-related macular degeneration:a systematic review and meta-analysis
by: Xiao-Yu Zhang, et al.
Published: (2014-04-01)

Comparative Safety of Bevacizumab, Ranibizumab, and Aflibercept for Treatment of Neovascular Age-Related Macular Degeneration (AMD): A Systematic Review and Network Meta-Analysis of Direct Comparative Studies
by: Anna A. Plyukhova, et al.
Published: (2020-05-01)

Primary treatment of diabetic macular edema
by: Tushar M Ranchod, et al.
Published: (2009-02-01)

A Clear Cell Renal Cell Carcinoma Inhibiting the Response to Intravitreal Antivascular Endothelial Growth Factor Therapy in Wet Age-Related Macular Disease
by: Manuel S. Falcão, et al.
Published: (2012-12-01)

Short-term results of early switch from Ranibizumab to Aflibercept in poor or non responder age related macular degeneration in clinical practice
by: Luciana de Sá Quirino-Makarczyk, et al.
Published: (2020-05-01)

Pharmacokinetics of Intravitreal Anti-VEGF Drugs in Age-Related Macular Degeneration
by: Laura García-Quintanilla, et al.
Published: (2019-07-01)

Autophagy: a new mechanism for regulating VEGF and PEDF expression in retinal pigment epithelium cells
by: Rong Li, et al.
Published: (2019-04-01)

Aqueous vascular endothelial growth factor and clinical outcomes correlation after single intravitreal injection of bevacizumab in patients with neovascular age-related macular degeneration
by: Thiago Cabral, et al.
Published: (2017-05-01)

Intravitreal pegaptanib for the treatment of ischemic diabetic macular edema
by: Kiire CA, et al.
Published: (2015-12-01)

Pharmacokinetics and Safety of an Intravitreal Humanized Anti-VEGF-A Monoclonal Antibody (PRO-169), a Biosimilar Candidate to Bevacizumab
by: Muñoz-Villegas P, et al.
Published: (2021-05-01)

Intravitreal injections: A review of pharmacological agents and techniques
by: Hasanain Shikari, et al.
Published: (2016-01-01)

A comparative debate on the various anti-vascular endothelial growth factor drugs: Pegaptanib sodium (Macugen), ranibizumab (Lucentis) and bevacizumab (Avastin)
by: Nagpal Manish, et al.
Published: (2007-01-01)

The role of anti-vascular endothelial growth factor (anti-VEGF) in the management of proliferative diabetic retinopathy
by: Yue Zhao, et al.
Published: (2018-08-01)

Decreased VEGF-A and sustained PEDF expression in a human retinal pigment epithelium cell line cultured under hypothermia
by: Masayuki Takeyama, et al.
Published: (2015-01-01)

Evaluation of the Safety of Bilateral Same-Day Intravitreal Injections of Anti-Vascular Endothelial Growth Factor Agents: Experience of a Large Korean Retina Center
by: Jang K, et al.
Published: (2020-10-01)

Transfer of single dose of intravitreal injection of ranibizumab and bevacizumab into milk of sheep
by: Tugba Cakmak Argun, et al.
Published: (2017-07-01)

Interlink between Inflammation and Oxidative Stress in Age-Related Macular Degeneration: Role of Complement Factor H
by: Sara Romero-Vazquez, et al.
Published: (2021-06-01)

Preliminary in vitro and in vivo assessment of a new targeted inhibitor for choroidal neovascularization in age-related macular degeneration
by: Li W, et al.
Published: (2016-10-01)

Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD
by: Maria Waizel, et al.
Published: (2017-05-01)

Exploring the Immunological Mechanisms Underlying the Anti-vascular Endothelial Growth Factor Activity in Tumors
by: Rodrigo Barbosa de Aguiar, et al.
Published: (2019-05-01)

Change of retinal pigment epithelial atrophy after anti-vascular endothelial growth factor treatment in exudative age-related macular degeneration
by: Moosang Kim, et al.
Published: (2016-01-01)

The effect of intravitreal bevacizumab and ranibizumab on macular edema of the contralateral eye: A comparative study of two anti-VEGFs
by: Berker Bakbak, et al.
Published: (2016-01-01)

Real-world outcomes of intravitreal antivascular endothelial growth factors for neovascular age-related macular degeneration in Taiwan: A 4-year longitudinal study
by: Benjamin Chi-Lan Yang, et al.
Published: (2019-01-01)

Introduction, mechanism of action and rationale for anti-vascular endothelial growth factor drugs in age-related macular degeneration
by: Kim Ramasamy
Published: (2007-01-01)

Intravitreal injection of Ranibizumab treating noninfectious uveitic macular edema
by: Hong-Bin Xie, et al.
Published: (2018-09-01)

Hypoxia Induced Heparan Sulfate Primes the Extracellular Matrix for Endothelial Cell Recruitment by Facilitating VEGF-Fibronectin Interactions
by: Jo Ann Buczek-Thomas, et al.
Published: (2019-10-01)

Therapeutic Potential of the Ranibizumab Port Delivery System in the Treatment of AMD: Evidence to Date
by: Chen ER, et al.
Published: (2020-05-01)

Retinal pigment epithelial tears after intravitreal bevacizumab injection for exudative age-related macular degeneration
by: Shaikh Saad, et al.
Published: (2007-01-01)

Control of Complement Activation by the Long Pentraxin PTX3: Implications in Age-Related Macular Degeneration
by: Matteo Stravalaci, et al.
Published: (2020-11-01)

Cannot write session to /tmp/vufind_sessions/sess_iff6g3aelbmab9nbulsqlf7n5p